Despite impressive third-quarter results and upbeat new guidance, Veeva Systems\u2019 share price took a sharp hit, falling nearly 10% in a single day, as investor jitters about future growth tempered enthusiasm. Even after this pullback, Veeva still boasts a 12.7% total shareholder return over the past year and remains solidly in positive territory for 2025. However, recent momentum has faded and the five-year total return lags the broader market.<\/p>\n
If you\u2019re interested in how other healthcare technology innovators are delivering growth and navigating changing markets, check out See the full list for free.<\/a><\/p>\n Given the mixed reaction to Veeva\u2019s earnings beat and guidance hike, the central question for investors is clear: does the recent pullback signal an undervalued opportunity, or is the market fully pricing in Veeva\u2019s growth trajectory from this point forward?<\/p>\n With the narrative\u2019s fair value estimate of $320.62 sitting well above Veeva\u2019s recent closing price of $244.06, there is a notable gap between the broader analyst consensus and where the market stands today. This invites a closer look at the high-conviction logic propelling this valuation.<\/p>\n The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers. This enables Veeva to fully integrate industry-leading datasets into its Commercial Cloud, which should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years.<\/p>\n Read the complete narrative.<\/a><\/p>\n Want to see what\u2019s fueling this bullish narrative? There\u2019s a bold blend of margin expansion, faster revenue growth, and a projected profit trajectory rarely seen in healthcare SaaS. Curious which assumptions are powering that premium? The full narrative spells out the aggressive financial blueprint behind this value call.<\/p>\n Result: Fair Value of $320.62 (UNDERVALUED)<\/p>\n Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n However, persistent competitive pressures or slower than expected adoption of Veeva\u2019s new AI products could quickly challenge this optimistic view.<\/p>\n Find out about the key risks to this Veeva Systems narrative.<\/a><\/p>\n Switching to a price-to-earnings lens, Veeva trades at 46.6x earnings, above both its fair ratio of 32.3x and the broader global healthcare services average of 34.1x. This suggests investors are paying a premium for growth today, which adds valuation risk if expectations reset. Will sentiment hold up if momentum slows?<\/p>\n See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a><\/p>\n Prefer to draw your own conclusions from the numbers? You can analyze the facts and put together a personalized investment narrative in just minutes. Do it your way<\/a><\/p>\n A good starting point is our analysis highlighting 4 key rewards<\/a> investors are optimistic about regarding Veeva Systems.<\/p>\n Don\u2019t let standout opportunities pass you by. Use the Simply Wall Street Screener to tap into some of the most compelling trends and strategies on the market right now.<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n Companies discussed in this article include VEEV<\/a>.<\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Veeva Systems (VEEV) delivered strong third-quarter results, beating revenue and earnings estimates while sharing an upbeat outlook for…\n","protected":false},"author":2,"featured_media":98052,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,82253,11628,14021,85,46,90710,90709],"class_list":{"0":"post-148314","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-business","9":"tag-earnings-estimates","10":"tag-fair-value","11":"tag-growth-trajectory","12":"tag-il","13":"tag-israel","14":"tag-veev","15":"tag-veeva-systems"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/148314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=148314"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/148314\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/98052"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=148314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=148314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=148314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/a> NYSE:VEEV PE Ratio as at Nov 2025 <\/p>\n